Identification and validation a costimulatory molecule gene signature to predict the prognosis and immunotherapy response for hepatocellular carcinoma

[1] Sung H(2020)GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin undefined undefined-undefined

[2] Ferlay J(2016)Hepatocellular carcinoma Nat Rev Dis Primers undefined undefined-undefined

[3] Siegel RL(2013)Complications of thermal ablation of hepatic tumours: comparison of radiofrequency and microwave ablative techniques Clin Radiol undefined undefined-undefined

[4] Global cancer statistics, JM(2015)Experimental evaluation of the heat sink effect in hepatic microwave ablation PLoS ONE undefined undefined-undefined

[5] Llovet J(2014)Differences in surgical outcomes between hepatitis B- and hepatitis C-related hepatocellular carcinoma: a retrospective analysis of a single North American center Ann Surg undefined undefined-undefined

[6] Zucman-Rossi E(2017)Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial Lancet undefined undefined-undefined

[7] Pikarsky J(2018)Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial Lancet Oncol undefined undefined-undefined

[8] Ding X(2020)Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study Lancet Oncol undefined undefined-undefined

[9] Jing J(2021)Hepatocellular carcinoma immunotherapy Annu Rev Med undefined undefined-undefined

[10] Liu KI(2020)Human anti-tumor immunity: insights from immunotherapy clinical trials Immunity undefined undefined-undefined

[1] Sung H(2020)GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin undefined undefined-undefined

[2] Ferlay J(2016)Hepatocellular carcinoma Nat Rev Dis Primers undefined undefined-undefined

[3] Siegel RL(2013)Complications of thermal ablation of hepatic tumours: comparison of radiofrequency and microwave ablative techniques Clin Radiol undefined undefined-undefined

[4] Global cancer statistics, JM(2015)Experimental evaluation of the heat sink effect in hepatic microwave ablation PLoS ONE undefined undefined-undefined

[5] Llovet J(2014)Differences in surgical outcomes between hepatitis B- and hepatitis C-related hepatocellular carcinoma: a retrospective analysis of a single North American center Ann Surg undefined undefined-undefined

[6] Zucman-Rossi E(2017)Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial Lancet undefined undefined-undefined

[7] Pikarsky J(2018)Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial Lancet Oncol undefined undefined-undefined

[8] Ding X(2020)Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study Lancet Oncol undefined undefined-undefined

[9] Jing J(2021)Hepatocellular carcinoma immunotherapy Annu Rev Med undefined undefined-undefined

[10] Liu KI(2020)Human anti-tumor immunity: insights from immunotherapy clinical trials Immunity undefined undefined-undefined